Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a consensus rating of “Hold” from the ten brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $18.67.

A number of equities research analysts have issued reports on HALO shares. BMO Capital Markets upped their price objective on Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Wednesday, September 27th. Barclays downgraded Halozyme Therapeutics from an “overweight” rating to a “hold” rating and upped their price objective for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. BidaskClub upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Canaccord Genuity upped their price objective on Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th.

Halozyme Therapeutics (NASDAQ HALO) traded up $0.09 during trading hours on Thursday, hitting $18.67. The company had a trading volume of 1,410,511 shares, compared to its average volume of 1,415,555. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics has a 12 month low of $9.68 and a 12 month high of $19.37.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The firm had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. Halozyme Therapeutics’s quarterly revenue was up 100.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. equities research analysts anticipate that Halozyme Therapeutics will post 0.15 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Halozyme Therapeutics by 4.8% during the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock valued at $148,652,000 after buying an additional 532,658 shares during the last quarter. Iridian Asset Management LLC CT grew its stake in shares of Halozyme Therapeutics by 2.0% during the second quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock valued at $136,007,000 after buying an additional 208,605 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Halozyme Therapeutics by 9.5% during the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after buying an additional 831,654 shares during the last quarter. BB Biotech AG grew its stake in shares of Halozyme Therapeutics by 6.7% during the second quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock valued at $105,961,000 after buying an additional 515,472 shares during the last quarter. Finally, Senzar Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 17.1% during the second quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock valued at $52,399,000 after buying an additional 597,400 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/30/halozyme-therapeutics-inc-halo-receives-consensus-rating-of-hold-from-brokerages.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.